Skip to content
Clinical Trials – home
Therapeutic area

Gastrointestinal disorders – page 77

  • 1 133 clinical trials
  • 489 recruiting
  • 474 conditions
  • 28 countries

Conditions in this area

474 conditions with trials, the busiest first

Clinical trials in Gastrointestinal disorders

1 133 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 133 clinical trials

Study of pembrolizumab and vorinostat combination therapy in patients with recurrent or metastatic squamous cell carcinoma of head and neck, cervix, anus, and genital areas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Unicancer

Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effectiveness of Autogene Cevumeran in Patients with ctDNA Positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Autogene Cevumeran
  • Sponsor:BioNTech SE

Gastric cancer

Not recruiting

Study of ALX148 with Trastuzumab, Ramucirumab, and Paclitaxel for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Alx Oncology Holdings Inc.

Study on the Effects and Safety of Crovalimab for Adults and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Everolimus
  • Sponsor:Rayzebio Inc.

Gastrooesophageal cancer+5

Not recruiting

Study of Nivolumab or Placebo for Patients with Removed Esophageal or Gastroesophageal Junction Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methoxyflurane
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Study Comparing Cisplatin and Radiotherapy with Durvalumab and Radiotherapy for Patients with Intermediate Risk HPV-Positive Oropharyngeal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Comparing drug combinations with panitumumab for patients with RAS and B-RAF wild-type metastatic colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Unicancer

Pancreatitis chronic

Not recruiting

Study on Tocilizumab for Reducing Pain in Patients with Chronic Pancreatitis

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Aalborg University Hospital

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.